Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157021 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3SMN1; SMN2USP2CTSK | |
| SCHEMBL2157015 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3SMN1; SMN2USP2CTSK | |
| SCHEMBL2157059 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3SMN1; SMN2USP2CTSK | |
| SCHEMBL3844539 | 0.86 | NR1H2 (0.46) | NR1H2ATMSMN1; SMN2USP2CTSK | |
| SCHEMBL19964291 | 0.86 | NR1H2 (0.38) | CA1CA2CA4CA9NR1H2 | |
| SCHEMBL4840168 | 0.85 | NR1H2 (0.46) | NR1H2ATMSETD7SMN1; SMN2USP2 | |
| SCHEMBL5790219 | 0.85 | NR1H2 (0.46) | NR1H2ATMSETD7SMN1; SMN2USP2 | |
| SCHEMBL28019383 | 0.84 | NR1H2 (0.40) | NR1H2NR1H3SMN1; SMN2USP2CTSK | |
| SCHEMBL4840180 | 0.83 | NR1H2 (0.40) | NR1H2ATMNR1H3SETD7SMN1; SMN2 | |
| SCHEMBL22709903 | 0.82 | NR1H2 (0.39) | NR1H2NR1H3SMN1; SMN2USP2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA1 3612/4885CA2 2065/4885CA4 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.